French biopharmaceutical flagship Sanofi announced that the U.S. Food and Drug Administration (FDA) has formally accepted the New Drug Application (NDA) and granted priority review status to its investigational asset, venglustat. The therapeutic molecule is a novel, brain-penetrant oral glucosylceramide synthase inhibitor (GCSi) developed for the treatment of type 3 Gaucher disease (GD3), a rare and debilitating lysosomal storage disorder. Upon potential regulatory clearance, venglustat would establish itself as the premier authorized therapeutic option inside the United States designed to directly address the progressive neurological manifestations driving GD3 pathology. The FDA has locked in a target Prescription Drug User Fee Act (PDUFA) action deadline for November 25, 2026.
The underlying pathology parameters, specialized molecular mechanisms, and clinical data profiles tracking the candidate outline:
-
Pathological Background and Blood-Brain Barrier Penetration: Gaucher disease is clinically characterized by the abnormal systemic accumulation of sugar-and-fat macromolecular building blocks known as glycosphingolipids (GSL) inside the spleen, liver, bone marrow, and lungs. In the specific sub-type defining GD3, these metabolic molecules supplementary accumulate within the central nervous system (CNS), triggering chronic neuroinflammation that clinically manifests as cognitive deficits, coordination failures, and loss of biological balance (ataxia). Engineered with the unique capacity to cross the blood-brain barrier, venglustat targets the clearing of central nervous system GSL pathophysiology, addressing critical unmet neurological needs that standard intravenous enzyme replacement therapies (ERT) cannot specifically intercept.
-
Pivotal Phase 3 Clinical Metrics: The regulatory NDA submission is structurally anchored in positive clinical data derived from the Phase 3 LEAP2MONO active-controlled study (ClinicalTrials.gov identifier: NCT05222906) involving adult and pediatric subjects aged 12 and older. The trial protocol evaluated the clinical efficacy and safety of a once-daily oral dose of venglustat against bi-weekly intravenous ERT infusions in stable patients whose systemic symptoms were previously managed via long-term ERT maintenance. Data presented at the annual WORLDSymposium™ documented that venglustat successfully met both primary study endpoints (measuring baseline-to-week-52 changes in the modified Scale for the Assessment and Rating of Ataxia [SARA] and the Repeatable Battery for the Assessment of Neuropsychological Status [RBANS]), alongside clearing three out of four key secondary endpoints.
-
Safety Profile and Adverse Events: The active therapeutic regimen was documented as well-tolerated overall, with clinical reviews signaling no novel safety anomalies. The most frequently reported adverse events localized within the active venglustat arm encompassed headache (14.3%), nausea (14.3%), spleen enlargement (14.3%), and diarrhea (14.3%).
-
Global Regulatory Trajectory: Reflecting its potential clinical utility, venglustat previously secured breakthrough therapy and fast-track designations from the U.S. FDA for GD3, alongside capturing orphan drug designations across the United States, European Union (EU), and Japan for both GD3 and Fabry disease pipelines. Parallel to the active FDA review window, the molecule is undergoing formal regulatory review by European authorities, with Sanofi preparing to launch supplementary global regulatory filings throughout the remainder of 2026.
Source: https://www.sanofi.com/en/media-room/press-releases/2026/2026-05-28-05-00-00-3302498